Patient preferences for non-small-cell lung cancer treatment: A quantitative study - Serena Oliveri
In this presentation, from the PREFER webinar of patient preferences for non-small-cell lung cancer treatment on 13 January 2022, Serena Oliveri shares the findings from the quantitative part of the PREFER lung cancer case study.
Watch the full webinar: https://youtu.be/1T9bpr3B06A
For more information about the project visit https://www.imi-prefer.eu/
The Patient Preferences in Benefit-Risk Assessments during the Drug Life Cycle (PREFER) project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115966. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
This video and its contents reflects the PREFER project's view and not the view of IMI, the European Union or EFPIA.
-
Category
No comments found